Financial Performance - Processed 3,664 EsoGuard tests and recognized revenue of $1.5 million for Q4 2025[9] - Total revenue for the year ended December 31, 2025, was $4.706 million, compared to $4.346 million in 2024[10] - GAAP net loss attributable to common stockholders was approximately $16.3 million, or $(0.12) per share for Q4 2025[10] - Non-GAAP adjusted loss for Q4 2025 was approximately $12.6 million, or $(0.10) per share[9] - Operating expenses for Q4 2025 were approximately $15.5 million, including stock-based compensation of $1.2 million[9] Business Development - Awarded a contract by the U.S. Department of Veterans Affairs for EsoGuard, expanding access to approximately nine million veterans[9] - The company aims to deepen relationships with the VA and expand adoption across health systems in 2026[5] - The company expects to secure Medicare coverage in the near term[5] Product Performance - EsoGuard achieved a 95% technical success rate in real-world data from nearly 12,000 at-risk patients[9] Cash Position - Cash and cash equivalents as of December 31, 2025, were $34.7 million, up from $22.4 million a year earlier[9]

Revenue Performance - Sypris Electronics reported a 27.6% increase in fourth quarter revenue to $17.7 million, but overall consolidated revenue decreased year-over-year due to tariffs and regulatory uncertainty affecting Sypris Technologies[3]. - For the full year 2025, Sypris Solutions reported revenue of $119.9 million, down from $140.2 million in 2024, with a net loss of $6.3 million compared to a net loss of $1.7 million in the prior year[9]. - Sypris Technologies experienced a revenue decline of 35.8% in Q4 2025, with revenue at $12.5 million compared to $19.5 million in Q4 2024[10]. Orders and Backlog - Year-to-date orders for Sypris Electronics increased by 58%, driven by missile program bookings and demand from U.S. Army and Navy programs[3]. - The backlog for energy products rose by 23% from year-end 2024, indicating strong future demand[3]. - Sypris Technologies has entered into a long-term sole-source agreement with a global truck OEM, with production expected to begin in 2027[3]. Profitability and Losses - Gross profit for Sypris Technologies in Q4 2025 was $1.3 million, or 10.2% of revenue, down from $4.4 million, or 22.5% of revenue, in the same period of 2024[10]. - Net loss for 2025 was $6,338,000, compared to a net loss of $1,680,000 in 2024, representing an increase in losses of approximately 276.2%[22]. Cash Flow and Assets - Net cash used in operating activities was $(5,731,000) in 2025, compared to net cash provided of $2,004,000 in 2024[22]. - Total current assets decreased from $98,018,000 in 2024 to $79,887,000 in 2025, a decline of approximately 18.4%[20]. - Cash and cash equivalents decreased from $9,675,000 in 2024 to $6,770,000 in 2025, a decrease of about 30.8%[22]. Inventory and Liabilities - Sypris Electronics faced $1.0 million in charges for excess and obsolete inventory in Q4 2025 due to changes in estimated future demand[11]. - Total liabilities decreased from $99,795,000 in 2024 to $90,021,000 in 2025, a reduction of approximately 9.8%[20]. - Accounts payable decreased from $18,428,000 in 2024 to $10,270,000 in 2025, a decrease of approximately 44.5%[20]. Equity and Capital Expenditures - Total stockholders' equity decreased from $19,581,000 in 2024 to $17,790,000 in 2025, a decline of approximately 9.1%[20]. - Capital expenditures decreased from $(1,083,000) in 2024 to $(756,000) in 2025, a reduction of about 30%[22]. Market Outlook - The company expects to benefit from robust markets in electronic warfare and secure communications, with increased demand anticipated due to geopolitical tensions[5]. - The company anticipates an improvement in the operating environment as it moves through 2026, supported by a strong backlog and new program wins[13].

Financial Performance and Projections - The company incurred net losses of $23.5 million and $34.0 million for the years ended December 31, 2025, and 2024, respectively, with an accumulated deficit of $198.6 million as of December 31, 2025[216]. - The company expects to continue incurring significant operating losses and expenses for the foreseeable future due to ongoing clinical trials and regulatory approval processes for its product candidates, particularly zervimesine[217]. - The company has $37.0 million in cash, cash equivalents, and restricted cash equivalents as of December 31, 2025, which is projected to fund operations through the second quarter of 2027[225]. - The company anticipates significant commercialization expenses if regulatory approval for zervimesine is obtained, impacting its financial position[224]. - The company expects to incur additional legal, accounting, and operational expenses as it operates as a public company, further straining its financial resources[217]. - The company may face increased costs and challenges in raising capital due to current economic conditions, including inflation and market volatility[228]. Product Development and Regulatory Challenges - The company is prioritizing the development of specific product candidates, particularly zervimesine, to address age-related degenerative diseases and disorders of the CNS and retina[235]. - The company currently has no products approved for sale, and zervimesine is in early stages of clinical development, which may take many years to demonstrate safety and efficacy[242]. - The success of the company’s business is heavily dependent on the successful development and regulatory approval of zervimesine and future product candidates[242]. - The company acknowledges that research and development of pharmaceuticals is inherently risky, with no assurance that any product candidates will receive regulatory approval[249]. - The company must navigate complex regulatory requirements in multiple jurisdictions, which could negatively affect revenue and operations if approvals are not obtained[252]. - The company has not conducted pivotal clinical trials for any of its product candidates, which may hinder its ability to obtain FDA approval[276]. - The FDA has granted accelerated approval to two monoclonal antibodies for Alzheimer's disease, but none for DLB, highlighting the limited success in drug development for these conditions[275]. - The company may encounter substantial delays in clinical trials due to various factors, including supply chain disruptions and regulatory disagreements[255]. - Clinical trials may face delays due to difficulties in patient enrollment, competition with other trials, and the need for adequate training of medical personnel[259][260]. Intellectual Property and Competitive Risks - The company relies on a combination of patents, trademarks, and trade secrets to protect its intellectual property, which is critical for its competitive position in the market[327]. - There is uncertainty regarding the patentability of the company's innovations, and failure to secure adequate patent protection could hinder future collaborations and commercialization efforts[330]. - The company may face challenges in defending its patents against third-party challenges, which could limit its ability to prevent competitors from entering the market with similar products[333]. - The company may need to license intellectual property from third parties, which may not be available on commercially reasonable terms, impacting its business[349]. - Third-party claims or litigation regarding patent infringement could delay or prevent the development and commercialization of the company's product candidates[351]. - The company cannot guarantee the successful enforcement of its patents, which may lead to invalidation or narrow interpretation of its intellectual property rights[361]. - Changes in U.S. patent law and international regulations could diminish the value of patents, affecting the company's ability to protect its lead product candidate, zervimesine[365]. Manufacturing and Supply Chain Risks - The company does not have the infrastructure or capability to manufacture its product candidates, relying entirely on contract manufacturers for compliance with regulatory requirements[388]. - The supply chain for the lead product candidate involves multiple manufacturers, indicating a complex logistical challenge that is expected to grow as development progresses[389]. - Any significant delay or quality control issue in the supply of product candidates could considerably delay preclinical or clinical trials and regulatory approval[390]. - The company has not yet engaged manufacturers for commercial supply, which could materially impact business if agreements cannot be established on reasonable terms[391]. - Risks associated with scaling up manufacturing to commercial scale include cost overruns and potential problems with process reproducibility and stability[393]. Market and Competitive Landscape - Significant competition exists in the neurodegenerative field, with major pharmaceutical companies and biotechnology firms pursuing similar product candidates[396]. - Competitors may have greater financial resources and expertise, which could impact the company's ability to successfully market its product candidates[398]. - Coverage and reimbursement from third-party payors are critical for the commercialization of product candidates, and failure to secure adequate reimbursement could limit marketability and revenue generation[400]. - International operations face extensive governmental price controls, impacting pricing and usage of product candidates[405]. - Increasing efforts to cap healthcare costs may limit coverage and reimbursement for newly approved products, leading to pricing pressures[406]. Compliance and Regulatory Risks - Regulatory approval does not eliminate ongoing scrutiny and compliance requirements for manufacturing and marketing[409]. - Compliance with FDA and foreign regulatory authority requirements is mandatory, necessitating continuous quality control and manufacturing adherence[410]. - Non-compliance with regulatory requirements could significantly affect the company's ability to commercialize products and generate revenue[413]. Strategic Initiatives and Collaborations - The company is exploring strategic collaborations to broaden its global reach, but there is uncertainty regarding the success and terms of such collaborations[305]. - The company may pursue acquisitions to enhance capabilities and market reach, but integration challenges and unanticipated costs could adversely affect financial results[306].

Financial Position - As of December 31, 2025, the company had cash and cash equivalents of $1,215.4 million, including $64.2 million in restricted cash[256]. - The total contractual obligations as of December 31, 2025, amounted to $5,156.2 million, with $2,575 million in gross long-term and short-term debt[275]. - The company recognized a net investment in a sales-type lease of $1,767.5 million for FLNG Gimi upon its commencement of operations on June 12, 2025[282]. - The company is in compliance with all covenants under its various loan agreements as of December 31, 2025[271]. Cash Flow Activities - Net cash provided by operating activities increased by $152.7 million in 2025, totaling $470.9 million compared to $318.2 million in 2024[261][264]. - Net cash used in investing activities rose by $396.2 million in 2025, amounting to $813.2 million, primarily due to higher capital expenditures of $506.9 million related to FLNG projects[266]. - Net cash provided by financing activities increased by $797.3 million in 2025, totaling $841.1 million, driven by $1,058 million in net proceeds from new debt issuances[268]. - Cash receipts from FLNG Gimi's operating revenues began following the commencement of operations in June 2025, contributing positively to cash flows[264]. Market Risks and Hedging - The company is exposed to various market risks, including interest rate, commodity price, and foreign currency exchange risks, and employs derivative instruments to hedge these risks[392]. - The company uses economic hedge agreements to manage interest rate risk, converting floating rate debt to fixed rate through interest rate swaps[394]. - A one-percentage point increase in the floating interest rate would increase the company's interest expense by $6.0 million per annum[395]. - A 10% depreciation of the U.S. Dollar would increase U.S. Dollar-denominated capital expenditures and operating expenses significantly, although specific figures were not provided[396]. - For the year ended December 31, 2025, a 10% reduction in the Brent linked crude oil price would decrease the realized gain on oil derivative instruments by $22.1 million[398]. - A 10% reduction in the TTF linked gas price and a 10% depreciation of USD against the Euro would decrease the realized gain on gas derivative instruments by $8.7 million for 2025[399]. Future Investments - The company plans to fund future investments and conversion projects through new loans, refinancing, and public/private debt or equity offerings[260]. - Changes in assumptions regarding lease cash flows and residual value estimates could materially impact the company's financial position in future periods[288]. Other Financial Information - The company reported a $7.1 million write-off of a shareholder loan to Higas due to its financial restructuring[257]. - As of December 31, 2025, the notional amount of interest rate swaps outstanding was $600.0 million, representing approximately 48.6% of the company's floating rate loans totaling $1.2 billion[395]. - The realized gain on oil derivative instruments is based on monthly billings above a base tolling fee of $60.00 per barrel for 1.2 million tonnes of LNG[398]. - The realized gain on gas derivative instruments is based on monthly billings above a contractual floor rate of $0.5652/MMBTu for 0.2 million tonnes of LNG[399].

Funding and Financials - Over $170 million in grants from NIH and others funded development through Phase 2[6] - The company has a cash runway through Q2 2027, with cash and equivalents totaling $37 million as of December 31, 2025[63] - The company has secured approximately $171 million in grant funding for zervimesine studies, with $36 million remaining[63] Clinical Efficacy - Zervimesine treatment stabilized psychotic symptoms in Phase 2, showing a 102% slowing of symptoms compared to placebo[7] - Phase 2 studies demonstrated efficacy across cognitive measures, particularly robust responses in participants with lower p-tau217 levels[14] - The NPI-4 analysis indicated a 102% slowing of psychotic symptoms in Zervimesine-treated participants relative to placebo[34] - Zervimesine demonstrated a 95% slowing of cognitive decline in lower p-tau217 participants in the SHINE study[40] - Participants with below median p-tau217 experienced a profound treatment effect, showing a 95% slowing in cognitive decline[54] Safety and Tolerability - Zervimesine has a favorable safety profile, well tolerated in over 450 individuals treated to date[7] - Zervimesine has shown a consistent safety profile, with adverse events balanced between treatment and placebo groups[57] Regulatory and Development Plans - The company plans to advance Zervimesine for DLB psychosis based on strong signals in behavioral and psychiatric symptoms[17] - Zervimesine is expected to be the first-to-market treatment for neuropsychiatric symptoms of dementia with Lewy bodies (DLB)[10] - The company received Fast Track designation for Zervimesine in Alzheimer's disease[10] - A new IND is required to transition to the FDA Division of Psychiatry, with a meeting scheduled for mid-May 2026[39] Study Details - The Phase 2 study enrolled 153 participants across multiple countries, with a mean MMSE score of 21.37 at entry[47] - The treatment period for the Phase 2 study was 6 months, focusing on safety, tolerability, and exploratory cognitive assessments[47] - The ongoing START study has completed enrollment with 545 participants, and topline results are anticipated in the second half of 2027[60] - The Expanded Access Program for DLB enrolled 32 participants, focusing on long-term safety and continued access to medication[36] Intellectual Property - Robust intellectual property protection for Zervimesine extends through 2040 with patent term extension[7] - The Phase 2 study of zervimesine in mild-to-moderate Alzheimer's disease was well-executed and over-enrolled, supporting further clinical development[46]

Clinical Trial Results - Gedatolisib, a pan-class I PI3K inhibitor, has shown a 63% objective response rate (ORR) among 103 patients in the Phase 1b clinical trial[339]. - The maximum tolerable dose (MTD) of gedatolisib was determined to be 180 mg administered intravenously once weekly[332]. - In the Phase 1b trial, Grade 3 or 4 hyperglycemia was reported in only 7% of patients, with less than 9% discontinuing treatment due to adverse events[340]. - The Phase 3 clinical trial VIKTORIA-1 has completed enrollment, focusing on HR+/HER2- advanced breast cancer patients[323]. - Gedatolisib's unique mechanism of action allows for comprehensive inhibition of the PI3K/AKT/mTOR pathway, overcoming limitations of therapies targeting single isoforms[327]. - The Phase 1b trial included 138 patients, with 35 enrolled in dose escalation arms to evaluate safety and tolerability[332]. - Gedatolisib is administered on a four-week cycle of three weeks-on, one week-off, which is better tolerated compared to oral PI3K and mTOR inhibitors[328]. - The Phase 1b trial's expansion arms showed an ORR of 85% for Arm A and 63% for Arm D, with progression-free survival (PFS) rates at 12 months of 72.1% and 53.2%, respectively[338]. - The median progression-free survival (PFS) for patients with PIK3CA mutated (MT) tumors was 14.6 months, with an overall response rate (ORR) of 48%[343]. - In the VIKTORIA-1 Phase 3 trial, the gedatolisib triplet demonstrated a median PFS of 9.3 months, reducing the risk of disease progression or death by 76% compared to fulvestrant (hazard ratio [HR] of 0.24)[347]. - The gedatolisib doublet showed a median PFS of 7.4 months, reducing the risk of disease progression or death by 67% compared to fulvestrant (HR of 0.33)[347]. - The ORR for the gedatolisib triplet was 31%, with a median duration of response (DOR) of 17.5 months, while the doublet had an ORR of 28.3% and a median DOR of 12.0 months[347]. - The VIKTORIA-1 trial achieved its enrollment goal of 351 subjects for the PIK3CA WT cohort by Q4 2024, with topline data for the PIK3CA MT cohort expected in Q2 2026[346]. - The six-month radiographic progression-free survival (rPFS) rate for patients in the CELC-G-201 trial was 67%, with a median rPFS of 9.1 months[358]. - The combination of gedatolisib and darolutamide was well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported[359]. - The median time to definitive deterioration for patients treated with the gedatolisib triplet was 23.7 months, compared to 4.0 months for fulvestrant[354]. - Gedatolisib is the first PAM pathway inhibitor to show positive Phase 3 results in HR+/HER2-/PIK3CA WT ABC patients who progressed after CDK4/6 inhibitor treatment[347]. - The overall response rate (ORR) among all patients enrolled in the gedatolisib trial was 43%[364]. - The median progression-free survival (PFS) was 6.0 months, with a 95% confidence interval (CI) of 5.0-7.7 months[364]. - The median overall survival was reported at 24.7 months, with a 95% CI of 17.3-NA[364]. Financial Performance - For the year ended December 31, 2025, the company reported a net loss of $177.0 million, compared to a net loss of $111.8 million in 2024, representing a 58% increase in losses[373]. - Research and development expenses for 2025 were $145.0 million, an increase of 39% from $104.2 million in 2024[374]. - General and administrative expenses rose to $27.2 million in 2025, a significant increase of 200% compared to $9.1 million in 2024[376]. - Interest expense for 2025 was $17.1 million, reflecting a 67% increase from $10.3 million in 2024[378]. - The company had an accumulated deficit of $448.9 million as of December 31, 2025[365]. - As of December 31, 2025, the company had $441.5 million in cash, cash equivalents, and short-term investments[365]. - Net cash used in operating activities was $153.3 million for the year ended December 31, 2025, compared to $83.5 million for 2024, reflecting a significant increase in operational losses[388][389]. - The company reported a net loss of $177.0 million for 2025, which included non-cash expenses of $26.4 million, primarily from stock-based compensation[388]. - Net cash used in investing activities was $64.1 million in 2025, with $63.9 million allocated to short-term investments in U.S. treasury securities[390]. - Financing activities generated $360.6 million in 2025, mainly from a $195.0 million Note Offering and a $91.6 million Equity Offering[392]. - The company experienced a net increase in cash and cash equivalents of $143.2 million in 2025, contrasting with a decrease of $8.1 million in 2024[387]. - Working capital changes in 2025 included a $15.4 million increase in accrued expenses, partially offset by a $15.1 million increase in prepaid expenses[388]. - The company may seek additional capital to fund operations and expansion, which could involve equity or convertible debt securities, potentially leading to stockholder dilution[386]. - Cash provided by financing activities in 2024 was $138.4 million, primarily from a $59.2 million Term C Loan and a $56.3 million equity offering[393]. - The company recorded $63.1 million in net cash used for investing activities in 2024, similar to the previous year, with a focus on short-term investments[391]. - The company’s management emphasizes that actual results may differ materially from estimates used in financial reporting, particularly regarding clinical trial costs and stock-based compensation[399][398]. Regulatory Milestones - The FDA has set a PDUFA goal date of July 17, 2026, for the potential approval of gedatolisib[367].

Product Development - The lead product candidate, ML-007C-MA, is being developed for schizophrenia and Alzheimer's disease psychosis, with a target enrollment of 300 participants expected by April 2026 for the Phase 2 trial ZEPHYR, and topline results anticipated in Q3 2026[20]. - ML-007C-MA has been evaluated in four Phase 1 trials with a total of 270 healthy participants and over 1,500 doses administered, demonstrating potential for well-tolerated treatment with convenient dosing[20]. - The company is also conducting a Phase 2 trial, IRIS, for ML-004, targeting social communication deficits in autism spectrum disorder, with topline results expected in Q3 2026[26]. - ML-009, a GPR52 PAM program for hyperactivity and impulsivity, is expected to complete IND-enabling studies in 2027[27]. - ML-055, a next-generation M1/M4 muscarinic agonist, aims to advance to IND-enabling studies in 2026[27]. - The pipeline includes diverse mechanisms and neural circuits to address various CNS disorders, retaining global development and commercial rights to all programs[29]. - The company utilizes a platform combining optogenetics, single-cell transcriptomics, and STARmap to identify druggable targets within disease-related neural circuits[32]. Unmet Medical Need - Approximately 40% of the 7 million people in the U.S. living with Alzheimer's disease experience symptoms of psychosis, indicating a significant unmet need for effective treatments[22]. - Approximately 30% of patients do not respond to dopaminergic antipsychotics, and 30% to 60% have only a partial response, highlighting a significant unmet medical need[38]. - There are currently no FDA-approved therapies for Alzheimer's disease psychosis, and off-label antipsychotics carry increased mortality risks in elderly patients[40]. - The current pipeline addresses significant disease burdens, with millions affected by CNS conditions, highlighting the need for innovative therapeutic options[28]. - There are currently no FDA-approved therapies for the core symptoms of ASD, highlighting the significant need for effective treatments[129][130]. Clinical Trials and Results - The Phase 2 ZEPHYR Study for schizophrenia aims to enroll approximately 300 participants, with a primary efficacy endpoint of change in total PANSS score from baseline to week 5[114][115][117]. - The ongoing Phase 2 VISTA trial employs a 1-week titration to reach the target maintenance dose for Alzheimer's disease patients[80]. - In the ongoing Phase 2 trials, ML-007C-MA will be dosed proximal to a meal, as tolerability was improved in fed conditions compared to fasted conditions[81]. - The ongoing clinical trials for ML-007C-MA include a double-blind, placebo-controlled design, with participants randomized to receive either placebo or ML-007C-MA 210/3 mg BID[121][115]. - The ongoing Phase 2 IRIS trial has enrolled approximately 160 participants with ASD to evaluate the efficacy of ML-004, with primary endpoint results expected after 12 weeks of maintenance dosing[143]. Safety and Efficacy - The safety profile of ML-007C-MA supported advancing doses up to 210/3 mg BID and 330/6 mg QD for the Phase 2 ZEPHYR trial in schizophrenia[75]. - Most treatment-emergent adverse events (TEAEs) were mild and transient, with no serious or severe adverse events reported during the trials[77]. - At the target doses for the ongoing Phase 2 ZEPHYR trial, 67% of participants receiving 330/6 mg experienced any TEAE, compared to 25% in the placebo group[98]. - ML-007 significantly improved spatial memory in a mouse model of Alzheimer's disease, while xanomeline did not show similar effects[85]. - The predicted CSF exposures for target doses of 210/3 mg BID and 330/6 mg QD were at or above the target range for most of the dosing period[76]. Regulatory and Compliance - The FDA granted Fast Track designation to ML-007C-MA in December 2025 for treating hallucinations and delusions associated with Alzheimer's disease psychosis[20]. - The FDA review process for new drugs typically takes about 10 months from the date of filing for a standard NDA, with a total review time of approximately 12 months[187]. - The FDA may issue an approval letter or a Complete Response Letter (CRL) after evaluating a New Drug Application (NDA) and conducting inspections of manufacturing facilities[189]. - A CRL indicates that the application will not be approved in its current form and may require additional clinical data or trials[189]. - The Fast Track designation program expedites the development and review of product candidates intended to treat serious diseases and address unmet medical needs[193]. Intellectual Property and Competition - As of December 31, 2025, the company holds approximately 86 issued patents and pending patent applications related to its product candidates and proprietary technology[151]. - The patent estate includes five issued foreign patents for ML-004, with pending applications expected to expire in 2040 and 2042, depending on the application[154]. - The company relies on trademarks, trade secrets, and know-how to maintain its competitive position in neuropsychiatric medicine, with seven trademark registrations as of February 25, 2026[160]. - The biotechnology and pharmaceutical industries are characterized by intense competition, with potential competitors having greater financial resources and established market presence[166][167]. - The company is developing ML-007C-MA for the treatment of schizophrenia, facing competition from existing antipsychotic treatments and other companies developing similar products[169][170].

Financial Performance - Acumen reported a net loss of $121.3 million for the year ended December 31, 2025, compared to a net loss of $102.3 million for the previous year, reflecting an increase of 18.5%[13] - Net loss for 2025 was $121.335 million, compared to a net loss of $102.329 million in 2024, reflecting a 18.6% increase in losses[23] - Net loss per common share, basic and diluted, was $2.00 in 2025, compared to $1.71 in 2024, indicating a 17.0% increase in loss per share[23] Research and Development - Research and Development (R&D) expenses increased to $104.9 million in 2025 from $93.8 million in 2024, primarily due to higher manufacturing and personnel-related costs[8] - Research and development expenses rose to $104.885 million in 2025, up from $93.798 million in 2024, a growth of 11.7%[23] - The company is targeting an Investigational New Drug (IND) filing for its lead clinical candidate in the EBD program by mid-2027[5] - The company expects to report topline results for the Phase 2 ALTITUDE-AD study of sabirnetug in late 2026, which will provide insights into the role of AβOs in Alzheimer's disease[5] - The first patient was dosed in the open-label extension of the ALTITUDE-AD trial in November 2025, allowing participants to receive sabirnetug for up to 52 weeks[8] - The company has enrolled 542 individuals in the ALTITUDE-AD trial, which is designed to evaluate the efficacy and safety of sabirnetug in early Alzheimer's disease patients[12] Cash and Assets - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $116.9 million, down from $136.1 million as of September 30, 2025, expected to support operations into early 2027[5] - Cash and cash equivalents at the end of the period increased to $54.220 million in 2025 from $35.859 million in 2024, a rise of 51.1%[25] - Acumen's total assets as of December 31, 2025, were $122.8 million, a decrease from $239.0 million in 2024[21] Operating Expenses - Total operating expenses increased to $123.832 million in 2025 from $114.017 million in 2024, representing an increase of 8.0%[23] - General and Administrative (G&A) expenses decreased to $18.9 million in 2025 from $20.2 million in 2024, attributed to reductions in recruiting and consulting costs[13] - Net cash used in operating activities was $115.538 million in 2025, compared to $86.215 million in 2024, an increase of 34.0%[25] Other Income and Securities - Total other income decreased significantly to $2.497 million in 2025 from $11.688 million in 2024, a decline of 78.6%[23] - Purchases of marketable securities were $38.056 million in 2025, down from $170.731 million in 2024, a decrease of 77.7%[25] - Proceeds from maturities and sales of marketable securities were $172.077 million in 2025, compared to $218.774 million in 2024, a decrease of 21.4%[25] Share Information - Weighted-average shares outstanding increased to 60,561,836 in 2025 from 60,013,277 in 2024, an increase of 0.9%[23] - Acumen announced a $35.75 million private placement in March 2026 to advance its AβO-selective Enhanced Brain Delivery (EBD) portfolio, following strong preclinical data[6]

Sales Performance - Sales decreased by $308,818 thousand, or 18.8%, to $1,335,121 thousand for the year ended December 31, 2025, primarily driven by a 40.8% decrease in silicon metals revenue [418]. - Silicon metal sales revenue decreased by $296,495 thousand, or 40.8%, with average selling prices falling by 10.4% to $2,924/MT in 2025 from $3,262/MT in 2024 [419]. - Manganese-based alloys sales revenue increased by $24,879 thousand, or 7.5%, despite a 3.0% decrease in average selling prices to $1,170/MT in 2025 [421]. - Sales in North America – Silicon Metals decreased by $102,034 thousand, or 26.4%, to $284,395 thousand for the year ended December 31, 2025, driven by a 4.1% decline in average selling prices and a 23.0% decrease in total shipments [434][435]. - Sales in North America – Silicon Alloys decreased by $13,973 thousand, or 5.0%, to $265,833 thousand for the year ended December 31, 2025, despite a 27.2% increase in total shipments [443][444]. - Sales in Europe – Manganese decreased by $3,569 thousand, or 1.0%, to $363,929 thousand for the year ended December 31, 2025, with total shipments increasing by 6.1% [451][452]. - Sales in Europe – Silicon Metals decreased by $172,332 thousand, or 43.8%, to $220,946 thousand for the year ended December 31, 2025, with average selling prices down by 16.2% [461][462]. - Sales in South Africa's Silicon Metals segment decreased by $60,100 thousand, or 88.5%, to $7,844 thousand for the year ended December 31, 2025, primarily due to the idling of the Polokwane facility [479]. - Sales in South Africa's Silicon Alloys segment decreased by $11,497 thousand, or 12.6%, to $79,524 thousand for the year ended December 31, 2025, with average selling prices down by 6.5% to $1,771/MT [488]. - Sales decreased by $32,186 thousand, or 17.7%, to $149,516 thousand for the year ended December 31, 2025, with average selling prices down by 3.3% to $1,898/MT [470]. Cost and Expenses - Raw materials and energy consumption for production decreased by $93,599 thousand, or 9.1%, to $933,531 thousand, with raw materials and energy consumption as a percentage of sales rising to 70% from 62% in 2024 [422]. - Staff costs decreased by $9,215 thousand, or 3.3%, to $270,649 thousand, primarily due to a reduction in variable remuneration reflecting weaker operating performance [424]. - Depreciation and amortization increased by $9,488 thousand, or 12.6%, to $84,951 thousand, driven by accelerated depreciation at the Alloys plant in the U.S. [426]. - Other operating expenses decreased by $23,154 thousand, or 27.5%, to $61,055 thousand for the year ended December 31, 2025, mainly due to lower CO2 consumption costs and reduced selling and distribution costs [467]. - Staff costs decreased by $9,797 thousand, or 13.7%, to $61,850 thousand for the year ended December 31, 2025, driven by lower variable remuneration in France and reduced costs at the Sabón facility [466]. - Raw materials decreased by $19,772 thousand, or 13.4%, to $127,870 thousand for the year ended December 31, 2025, driven by lower shipments and a favorable product mix [471]. Financial Performance - EBITDA for 2025 was $(72,392) thousand, compared to $127,209 thousand in 2024, reflecting a significant decline in performance [507]. - FX Adjusted EBITDA for 2025 was $(48,506) thousand, down from $113,644 thousand in 2024 [507]. - Cash flows from operating activities decreased by $191,794 thousand, to $51,464 thousand for the year ended December 31, 2025, primarily due to a net loss of $177,112 thousand compared to a net profit of $20,800 thousand in 2024 [540]. - Cash flows used in investing activities increased by $6,195 thousand to an outflow of $73,132 thousand for the year ended December 31, 2025, driven by financial investments in Norway and the U.S. [541]. - Total outstanding debt as of December 31, 2025, was $269,152 thousand, with $129,551 thousand in short-term debt and $112,431 thousand in long-term debt [517]. - Cash and cash equivalents, including restricted cash, amounted to $122,987 thousand as of December 31, 2025 [513]. - Cash and cash equivalents at the end of the period decreased to $122,987 thousand from $133,271 thousand in 2024 [539]. - Total contractual obligations as of December 31, 2025, amounted to $885,535 thousand, with significant future cash outlays required [536]. Impairment and Losses - Impairment losses decreased by $25,564 thousand, or 59.4%, to $17,488 thousand for the year ended December 31, 2025, with significant impairments recognized in the Silicon Metal cash-generating unit [427]. - Impairment losses in Europe – Manganese increased by $5,062 thousand, or 192.6%, to $7,691 thousand for the year ended December 31, 2025, reflecting updated market conditions [460]. - The Company recorded a $5,862 thousand impairment loss in its Puertollano facility for the year ended December 31, 2024, which did not repeat in 2025 [503]. - Operating loss for the Silicon Alloys segment was $33,876 thousand in 2025, compared to a loss of $7,441 thousand in 2024 [469]. - Overall operating loss for the Other Segments increased to $25,941 thousand for the year ended December 31, 2025, compared to a loss of $34,892 thousand in 2024 [495]. Tax and Finance - Finance income decreased by $3,774 thousand, or 52.1%, to $3,474 thousand, while finance costs decreased by $1,167 thousand, or 5.3%, to $20,775 thousand [428][429]. - Income tax expense decreased by $13,784 thousand, or 71.8%, to $2,468 thousand for the year ended December 31, 2025, primarily due to a $101,428 thousand decline in pre-tax results in France [431]. Market Conditions - The decline in sales was attributed to increased competition from low-priced imports and weak steel demand, particularly in construction and automotive sectors [470]. - The company experienced a significant reduction in CO2 emissions linked to lower production levels, contributing to overall cost savings [465].

Market Growth and Sales - Rockwell Medical's hemodialysis concentrates market in the U.S. is projected to grow from $450 million in 2024 to approximately $560 million by 2028, driven by an increasing number of patients suffering from end-stage kidney disease [40]. - In 2025, Rockwell Medical served 294 customers, including all five leading dialysis providers in the U.S., with DaVita accounting for 16% of total net product sales [42]. - Rockwell Medical's total international sales accounted for approximately 12% of total sales in 2025, up from 9% in 2024 [46]. - Rockwell Medical's concentrates accounted for 100% of revenue for the year ended December 31, 2025, with approximately 88% of sales directed to U.S. distributors and customers [42]. - DaVita accounted for 16% of net sales in 2025, down from 45% in 2024, reflecting a significant decline in product purchases [209]. Product Development and Agreements - The company added a single-use bicarbonate cartridge to its product portfolio in February 2025, which is 510(k) approved by the FDA and available in sizes of 720 grams and 900 grams [22]. - In 2025, Rockwell Medical signed a multi-year product purchase agreement with Innovative Renal Care, one of the largest dialysis service providers in the U.S. [29]. - The company extended its product purchase agreement with DaVita through December 31, 2026, with an increase in product pricing for the extended term [43]. - The company entered into an Amended and Restated Products Purchase Agreement with DaVita, extending the term to December 31, 2025, with quarterly non-refundable payments of $2.0 million for supply continuity [204]. Financial Performance - Net sales for the year ended December 31, 2025, were $69.3 million, a decrease of 31.8% from $101.5 million in 2024, primarily due to a $34.6 million reduction in sales to DaVita [208][209]. - Gross profit for 2025 was $11.7 million, representing 16.9% of revenue, compared to $17.5 million and 17.2% in 2024, indicating a 33.1% decrease [208][211]. - Cost of sales decreased to $57.6 million in 2025 from $84.0 million in 2024, contributing to the overall decline in gross profit [211]. - Selling and marketing expenses were $2.4 million in 2025, down from $2.7 million in 2024, due to lower marketing costs and reduced employee compensation [212]. - General and administrative expenses slightly decreased to $14.0 million in 2025 from $14.1 million in 2024, with increases in stock-based compensation and employee compensation offset by reductions in administrative expenses [213]. Regulatory Compliance and Risks - The company is subject to stringent regulatory requirements, including compliance with the FDA's Quality System Regulation (QSR) and postmarket surveillance regulations, which could impact operations if not adhered to [79]. - Noncompliance with FDA regulations can result in fines, product recalls, or suspension of production [58]. - The FDA requires a premarket notification for Class II devices, which must demonstrate substantial equivalence to legally marketed predicate devices [65]. - The PMA process for Class III devices is generally more costly and time-consuming than the 510(k) process, requiring extensive data to demonstrate safety and effectiveness [72]. - The company is subject to extensive regulation by the FDA and other authorities, which can impose significant costs and operational restrictions [142]. Competition and Market Challenges - The company faces significant competition in the concentrates market from large competitors like Fresenius and Nipro, which have greater financial and technical resources [97]. - The evolving treatment landscape for end-stage kidney disease (ESKD) may reduce demand for the company's hemodialysis concentrate products due to advancements in treatment modalities and new pharmacologic therapies [101]. - Increased adoption of home-based dialysis modalities may reduce reliance on in-center hemodialysis services, impacting demand for traditional hemodialysis [102]. - Changes in Medicare and Medicaid funding could impact the ability of dialysis providers to pay in full, increasing the risk of uncollectible accounts [114][115]. - The dialysis provider industry may continue to consolidate, leading to increased purchasing leverage for providers and pricing pressure on suppliers [117]. Operational and Financial Stability - The company has limited capital resources and may require additional funding to operate and expand its business, which may not be available on favorable terms [99]. - The company has a cumulative deficit of approximately $403.0 million since inception, indicating ongoing financial challenges [135]. - The amended loan agreement requires actual consolidated revenue from hemodialysis products to be at least 85% of projections for the trailing six-month period, decreasing to 80% starting September 30, 2024 [132]. - The company may be forced to implement further cost-saving measures if it cannot increase revenues or raise necessary capital, potentially impacting operations [136]. - The company may face risks from economic downturns, inflation, and geopolitical events, which could adversely affect financial performance [99]. Employee and Corporate Governance - The company has 157 employees as of December 31, 2025, with no collective bargaining agreements in place, and emphasizes employee retention and motivation through compensation and benefits [91][92]. - The company is highly dependent on retaining key personnel, and competition for qualified employees is intense, leading to rising compensation costs [122][123]. - The Board of Directors oversees cybersecurity risks, with the Audit Committee regularly interacting with the Chief Operating Officer [176]. - Rockwell Medical has implemented a comprehensive cybersecurity risk management program integrated into its overall enterprise risk management strategy [172]. Legal and Liability Risks - The company has experienced significant legal risks, including potential litigation that could adversely affect its business and financial condition [146]. - The company sells hemodialysis concentrates and previously marketed Triferic, which may expose it to product liability claims due to undesirable side effects [147]. - The company maintains product liability insurance, but there is uncertainty regarding its sufficiency to cover potential liabilities, which could harm its reputation and financial position [148]. - The company may face claims of intellectual property infringement, which could prevent product sales and result in significant damages [149]. - The company has previously faced proxy contests, which have incurred substantial costs and could interfere with its strategic plans [153]. Stock and Market Position - The company moved its listing to The Nasdaq Capital Market and executed an 11-for-1 reverse stock split to regain compliance with minimum bid price requirements [158]. - The company has substantial net operating loss carryforwards that may be limited in their use due to potential ownership changes [161]. - The company does not anticipate paying dividends in the foreseeable future, as it intends to retain earnings to finance operations [162]. - The company has experienced fluctuations in its common stock price, which may lead to litigation and impact its profitability [155].